2. Academic Validation
  3. Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations

Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations

  • Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01717-19. doi: 10.1128/AAC.01717-19.
Francesco Saladini 1,  Alessia Giannini 2,  Adele Boccuto 2,  Filippo Dragoni 2,  Alice Appendino 2,  Edoardo Albanesi 2,  Ilaria Vicenti 2,  Maurizio Zazzi 2
Affiliations

Affiliations

  • 1 Department of Medical Biotechnologies, University of Siena, Siena, Italy [email protected].
  • 2 Department of Medical Biotechnologies, University of Siena, Siena, Italy.
PMID: 31611362 DOI: 10.1128/AAC.01717-19
Abstract

Second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) dolutegravir (DTG), bictegravir (BIC), and cabotegravir (CAB) showed a high genetic barrier to resistance and limited cross-resistance with first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG). In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q148H/K/R plus one to two additional INSTI mutations.

Keywords

HIV-1 resistance; bictegravir; cabotegravir; dolutegravir; integrase inhibitors; phenotypic assay.

Figures
Products